Reduced nasal nitric oxide in diffuse panbronchiolitis

Area of Science:

• Pulmonary Medicine
• Respiratory Physiology
• Medical Diagnostics

Background:

• Diffuse panbronchiolitis (DPB) is a chronic inflammatory airway disease characterized by respiratory bronchiolitis, bronchiectasis, and sinusitis.
• Patients with DPB experience recurrent airway infections due to impaired mucociliary function.
• Low nasal nitric oxide (NO) is typically associated with primary ciliary dyskinesia syndrome and cystic fibrosis.

Purpose of the Study:

• To investigate whether patients with DPB exhibit abnormal nasal nitric oxide (NO) levels.
• To determine if nasal NO measurement can serve as a diagnostic marker for DPB.

Main Methods:

• Nasal NO levels were measured using the chemiluminescence technique in 15 healthy subjects and 8 patients diagnosed with DPB.
• Air samples were collected directly from the nasal passages of all participants.
• The effect of erythromycin treatment on nasal NO was assessed in four control subjects.

Main Results:

• Nasal NO levels in DPB patients were significantly lower (88%) compared to age-matched healthy controls (69 +/- 70 nl/min vs. 556 +/- 87 nl/min, p < 0.001).
• A 2-week course of erythromycin treatment did not alter nasal NO levels in the control subjects studied.
• This study identifies DPB as the third pulmonary disease associated with reduced nasal NO.

Conclusions:

• Reduced nasal NO is a characteristic finding in patients with diffuse panbronchiolitis (DPB).
• Low nasal NO levels may be implicated in the pathogenesis of DPB.
• Nasal NO measurement presents a potential noninvasive diagnostic tool for identifying DPB.